fMRI predicts response to liver tumor treatment

Article

Contrast enhancement and metabolic changes detected with functional MR imaging can help interventional radiologists anticipate the effects of transarterial chemoembolization on primary and metastatic tumors of the liver.

Contrast enhancement and metabolic changes detected with functional MR imaging can help interventional radiologists anticipate the effects of transarterial chemoembolization on primary and metastatic tumors of the liver.

Clinical trials from Johns Hopkins University and Northwestern University come on the heels of a third study showing that contrast-enhanced and diffusion-weighted MRI can confirm the effects of transarterial chemoembolization (TACE) on liver metastases from neuroendocrine tumors. Results were presented March 17 at the 2008 Society of Interventional Radiology meeting.

Northwestern medical student Neel K. Naik and colleagues enrolled 21 patients with hepatocellular carcinoma who underwent TACE and pre- and postprocedural 1.5T gadolinium-enhanced T1-weighted MR and DWI with follow-up at one and three months. They found DWI changes a few weeks after treatment began that were useful for predicting TACE effects two months before they actually took place and became evident with anatomic MRI and other types of imaging.

Previous research has shown that functional MRI can characterize liver lesions, but no study to date had looked at the possibility of predicting response to TACE, Naik said.

In another study, interventional radiology fellow Dr. Josephina A. Vossen and colleagues at Johns Hopkins evaluated 19 patients with unresectable primary or metastatic liver tumors treated with TACE. Patients underwent unenhanced/contrast-enhanced MRI and MR spectroscopy before and after a single treatment. Two radiologists interpreted results by consensus.

They found 11 patients with successful tumor embolization showed loss of choline peak on MR spectroscopy, significant increase in apparent diffusion coefficient values (22%, p = 0.004), and significant decrease in tumor arterial and venous enhancement (43%, p = 0.005 and 40%, p = 0.002, respectively). Patients with no evidence of tumor response had a stable choline concentration, tumor enhancement, and ADC.

"These functional findings preceded tumor regression in size and may be utilized to detect early therapeutic response," Vossen said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.